Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $12.58, up 0.00% on the session, giving a market capitalisation of $718.1M. On trailing twelve-month figures it carries a trailing P/E of -7.40, a net margin of -13938.2%. Its beta of 0.02 implies it has historically moved less than the broad market.
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.
Astria Therapeutics, Inc. is most often compared with the following Healthcare names: